Oxford BioTherapeutics
  • ABOUT
    • OUR TEAM
    • BOARD OF DIRECTORS
    • INVESTORS
    • OFFICES & LABS
  • PIPELINES
    • INTERNAL PROGRAMS
    • PARTNERED PROGRAMS
  • PARTNERSHIPS
  • OUR SCIENCE
    • IO DISCOVERY PLATFORM >
      • IMMUNE CHECKPOINT TARGETS
      • IO ANTIBODY ENGINEERING
    • OGAP DISCOVERY PLATFORM
    • PUBLICATIONS
  • CAREERS
  • NEWS
    • PRESS RELEASES
    • OBT in the News
  • CONTACT

PRESS RELEASES

Beyond PDL1: OBT has recently discovered a novel T cell modulatory axis, OX001R/L, which is involved in cancer immune escape independent of the PD1/PDL1 axis. "

Press Releases

​2023

Date
Title
Details
09 Mar 2023
 Oxford BioTherapeutics  to Announce New Fully Integrated ADC Engine at the World ADC Conference 2023
View here
07 Mar 2023
 Oxford BioTherapeutics  wins Tech Company of the Year and Special Recognition Award at Thames Valley SME Growth 100 Awards
View here

​2022

Date
Title
Details
13 June 2022
 Oxford BioTherapeutics  enters into Commercial License Agreement with Genmab
View here
13 June 2022
Oxford BioTherapeutics  Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates
View here
27 May 2022
Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022
View here
​25 May 2022
  Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in Combination with Agenus CPI Balstilimab
View here
​13 April 2022
Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology target 
View here
​07 April 2022
AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076 
View here

​2021

Date
Title
Details
20 Sept 2021
 Boehringer Ingelheim and Oxford BioTherapeutics Partnership Advances Second Oncology Drug Candidate into the Clinic
View here
19 Jan 2021
 
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics' WuXiBody® Platform
View here
06 Jan 2021
Kite and Oxford BioTherapeutics Establish Cell therapy Research Collaboration in Blood Cancers and Solid Tumours
View here

2020

Date
Title
Details
14 Oct 2020
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic
View here
09 Jan 2020
Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors ​
View here

2019

Date
Title
Details
25 Jun 2019
​
Oxford BioTherapeutics Announces Receipt of a Milestone Payment as Boehringer Ingelheim Advances an Oncology Drug Candidate 
View here

2018

Date
Title 
Details
21 Dec 2018
Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076: An Experimental First in Class ADC Medicine for High Risk Her2 Negative Breast Cancer, Gastric, Lung, Bladder and Ovarian Cancer Patients - US Phase I Clinical Trial to be Initiated
View here
11 Dec 2018
Oxford BioTherapeutics Expands Strategic Collaboration with  WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million
View here
01 Mar 2018
​Oxford BioTherapeutics Appoints Chief Medical Officer, ​Abderrahim Fandi
View here

2017

Date
Title
Details
13 Jun 2017
​Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director
View here
09 Feb 2017
Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans​​​​​
View here
26 Jan 2017
Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics​​
View here

2016

Date
Title
Details
18 Apr 2016
Boehringer Ingelheim Exercises Option on Second Oncology Target using Oxford BioTherapeutics’ OGAP® System​
View here
04 Apr 2016
Oxford BioTherapeutics Licenses Nerviano Medical Sciences’ Drug-Linker Technology to Develop Novel Antibody Drug Conjugates
View here

Media

Immunotherapies Expose and Exploit Cancer’s Varied Weaknesses
March 18 2021: “If we could understand why some people reengage their immune system after receiving chemotherapy, while others don’t, we could think about how to combine various therapeutic modalities and in what sequence”, says Christian Rohlff, PhD, CEO of Oxford BioTherapeutics. Read more here about how OBT uses proprietary immuno-oncology technology and antibody-drug conjugates to develop novel therapeutics that can reengage the immune system to destroy cancer cells.

Privacy Policy

Legal Notice

Site Map

© 2017 Oxford BioTherapeutics All Rights Reserved
  • ABOUT
    • OUR TEAM
    • BOARD OF DIRECTORS
    • INVESTORS
    • OFFICES & LABS
  • PIPELINES
    • INTERNAL PROGRAMS
    • PARTNERED PROGRAMS
  • PARTNERSHIPS
  • OUR SCIENCE
    • IO DISCOVERY PLATFORM >
      • IMMUNE CHECKPOINT TARGETS
      • IO ANTIBODY ENGINEERING
    • OGAP DISCOVERY PLATFORM
    • PUBLICATIONS
  • CAREERS
  • NEWS
    • PRESS RELEASES
    • OBT in the News
  • CONTACT